Contact

Our portfolio

Primagen

Primagen Holding focuses on developing molecular diagnostic tests and investing in bio- and medtech startups. The company generates revenues through the licensing of their diagnostics technology. Primagen Holding’s portfolio includes investments in PulseCath and Akkolens International.

  • Institute: Amsterdam UMC
Industry: Diagnostics, Infectious Disease
  • Founding year: 1993
Visit website

Want to get in contact about Primagen?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Browse all investment managers

Marc Roelofs

Life Science & Health

Our portfolio

Check out similar ventures

Deep Sleep Technologies
Enhancing deep sleep through real-time, non-invasive brainwave stimulation using adaptive, science-backed algorithms.
Glass Medical AI
Stratifying patients for oncology trials with explainable AI on pathology data.
AviSia Therapeutics
Modulating immune responses with glycan-modified antigens for the treatment of Type 1 Diabetes.
InspectT
Enabling standard spectrometers to simultaneously measure both chemical composition and particle size by integrating patented, cost-effective Optical-DOSY flow cells.
Deep Sleep Technologies
Enhancing deep sleep through real-time, non-invasive brainwave stimulation using adaptive, science-backed algorithms.
Glass Medical AI
Stratifying patients for oncology trials with explainable AI on pathology data.
AviSia Therapeutics
Modulating immune responses with glycan-modified antigens for the treatment of Type 1 Diabetes.
InspectT
Enabling standard spectrometers to simultaneously measure both chemical composition and particle size by integrating patented, cost-effective Optical-DOSY flow cells.
Explore full AAV portfolio
Contact